论文部分内容阅读
目的探讨胺碘酮治疗充血性心力衰竭心律失常的临床疗效与安全性。方法选取80例充血性心力衰竭(CHF)合并室性心律失常患者,随机分为对照组和治疗组,对照组给予常规抗心衰治疗,治疗组在对照组治疗基础上加用胺碘酮治疗,对比分析两组患者在心功能改善、抗心律失常、左室射血分数(LVEF)、心律衰竭再入院率及药物不良反应等反面的情况。结果胺碘酮组在抗心律失常、心功能改善、左室射血分数、心律衰竭再入院率等方面均明显优于对照组,差异有统计学意义(P<0.05)。结论胺碘酮是治疗充血性心力衰竭合并室性心律失常有效的药物,使用安全。
Objective To investigate the clinical efficacy and safety of amiodarone in the treatment of arrhythmia of congestive heart failure. Methods Eighty patients with congestive heart failure (CHF) complicated with ventricular arrhythmia were randomly divided into control group and treatment group. The control group was given routine anti-heart failure treatment. The treatment group was treated with amiodarone on the basis of the control group . The adverse reactions such as cardiac function improvement, anti-arrhythmia, left ventricular ejection fraction (LVEF), re-admission rate of arrhythmia and adverse drug reaction were compared between the two groups. Results The amiodarone group was significantly better than the control group in antiarrhythmic, cardiac function improvement, left ventricular ejection fraction and rehospitalization rate of heart failure, the difference was statistically significant (P <0.05). Conclusion Amiodarone is effective in treating congestive heart failure complicated with ventricular arrhythmia.